Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting

Trial ID or NCT#

NCT02042157

Status

not recruiting iconNOT RECRUITING

Purpose

Our expectations (hypotheses) are: Primary outcome 1. Regular bidet use will improve quality of life around elimination in adults with impaired functional status. Functional status will be measured by activities of daily living (ADL). 2. Regular bidet use by adults with impaired functional status will improve the quality of life around toileting for their caregivers. Secondary 3. Regular bidet use will reduce the incidence, frequency and severity of constipation (as measured by self-report) in adults with impaired functional status. 4. Regular bidet use will reduce the incidence of urinary tract infection (UTI) in adult women with impaired functional status.

Official Title

Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting

Eligibility Criteria

Ages Eligible for Study: 21 Years to 95 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. Sample 1 (adults with impaired functional status):
  2. Age: 55-95 Sex: Female Ethic background: Reflecting the population at Stanford Hospital and Clinics who meet the inclusion criteria and who agree to participate.
  3. Sample 2 (caregivers of participants in Sample 1) Adults over the age of 21 caring for an adult with impaired functional status who has enrolled in this randomized controlled trial. Sex and ethnic background will reflect the demographic of the caregivers for the population in Sample 1.
Exclusion Criteria:
  1. Participants not meeting the inclusion criteria.
  2. Additional exclusion criteria:
    1. 1. Life expectancy less than 2 years2. The inability to read and write English.3. Patients with indwelling urinary (e.g. Foley) catheters4. Use of any water based cleaning system after toileting at home in the past 12 months (bidet, water pot, douche etc).5. Fully incontinent (eg diaper use)6. Moderate to severe cognitive impairment (15 or lower on the MOCA)

Contact us to find out if this trial is right for you.

Contact

Isabella Chu, MPH
650-723-2513